Topical chemotherapy in cutaneous T-cell lymphoma: Positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides

JAMA Dermatology

Volumn 149, Issue 1, 2013, Pages 25-32

  Lessin, Stuart R ^a,n   Duvic, Madeleine ^c   Guitart, Joan ^e   Pandya, Amit G ^d   Strober, Bruce E ^f   Olsen, Elise A ^g   Hull, Christopher M ^h   Knobler, Elizabeth H ⁱ   Rook, Alain H ^b   Kim, Ellen J ^b   Naylor, Mark F ^j   Adelson, David M ^j   Kimball, Alexa B ^k   Wood, Gary S ^l   Sundram, Uma ^m   Wu, Hong ^a   Kim, Youn H ^m  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF CONNECTICUT   (United States)

^g DUKE UNIVERSITY   (United States)

^h UNIVERSITY OF UTAH   (United States)

ⁱ Och Spine at New York Presbyterian Hospitals   (United States)

^j UNIVERSITY OF OKLAHOMA   (United States)

^k HARVARD MEDICAL SCHOOL   (United States)

^l UNIVERSITY OF WISCONSIN MADISON   (United States)

^m STANFORD CANCER INSTITUTE   (United States)

ⁿ Bryn Mawr Skin and Cancer Institute   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BEXAROTENE; CARMUSTINE; CHLORMETHINE; CORTICOSTEROID; EMOLLIENT AGENT; INTERFERON; METHOTREXATE; RETINOID DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; BLOOD CHEMISTRY; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CHILD; CLINICAL ASSESSMENT TOOL; COMPOSITE ASSESSMENT OF INDEX LESION SEVERITY; CONTACT DERMATITIS; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FOLLICULITIS; GEL; HEMATOLOGICAL PARAMETERS; HUMAN; HYPERPIGMENTATION; MAJOR CLINICAL STUDY; MALE; MERKEL CELL TUMOR; MODIFIED SEVERITY-WEIGHTED ASSESSMENT TOOL; MULTICENTER STUDY; MYCOSIS FUNGOIDES; OINTMENT; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SECOND CANCER; SIDE EFFECT; SKIN CARCINOMA; SKIN IRRITATION; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; FEMALE; GELS; HUMANS; MALE; MECHLORETHAMINE; MIDDLE AGED; MYCOSIS FUNGOIDES; NEOPLASM STAGING; OINTMENTS; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873435187     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/2013.jamadermatol.541     Document Type: Article

References (24)

1. Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLennan MT. Landmark article Sept. 21, 1946: Nitrogen mustard therapy: use of methylbis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. JAMA. 1984;251(17):2255-2261. (Pubitemid 14135443)
2. Bunn PA Jr, Hoffman SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). Ann Intern Med. 1994;121(8):592-602.
3. Haserick J, Richardson J, Grant D. Remission of lesions in mycosis fungoides following topical application of nitrogen mustard. Cleve Clin Q. 1959;26:144-147.
4. Sipos K. Painting treatment of nitrogen mustard in mycosis fungoides. Dermatologica. 1965;130:3-11.
5. Ramsay DL, Meller JA, Zackheim HS. Topical treatment of early cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995;9(5):1031-1056.
6. Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol. 2003;139(2):165-173. (Pubitemid 36216254)
7. Van Scott EJ. Complete regressions of mycosis fungoides with topical mechlorethamine hydrochloride. JAMA. 1972;222(9):1172.
8. Van Scott EJ, Kalmanson JD. Complete remissions of mycosis fungoides lymphoma induced by topical nitrogen mustard (HN2): control of delayed hypersensitivity to HN2 by desensitization and by induction of specific immunologic tolerance. Cancer. 1973;32(1):18-30.
9. Price NM. Topical mechlorethamine: cutaneous changes in patients with mycosis fungoides after its administration. Arch Dermatol. 1977;113(10):1387- 1389.
10. Vonderheid EC, Van Scott EJ, Wallner PE, Johnson WC. A 10-year experience with topical mechlorethamine for mycosis fungoides: comparison with patients treated by total-skin electron-beam radiation therapy. Cancer Treat Rep. 1979;63(4):681-689. (Pubitemid 9217598)
11. Price NM, Deneau DG, Hoppe RT. The treatment of mycosis fungoides with ointment-based mechlorethamine. Arch Dermatol. 1982;118(4):234-237. (Pubitemid 12142600)
12. Hamminga B, Noordijk EM, Van Vloten WA. Treatment of mycosis fungoides: totalskin electron-beam irradiation vs topical mechlorethamine therapy. Arch Dermatol. 1982;118(3):150-153. (Pubitemid 12185303)
13. Ramsay DL, Parnes RE, Dubin N. Response of mycosis fungoides to topical chemotherapy with mechlorethamine. Arch Dermatol. 1984;120(12):1585-1590. (Pubitemid 15176041)
14. Ramsay DL, Halperin PS, Zeleniuch-Jacquotte A. Topical mechlorethamine therapy for early stage mycosis fungoides. J Am Acad Dermatol. 1988;19(4):684-691.
15. Vonderheid EC, Tan ET, Kantor AF, Shrager L, Micaily B, Van Scott EJ. Longterm efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol. 1989;20(3):416-428. (Pubitemid 19086776)
16. Kim YH, Jensen RA, Watanabe GL, Varghese A, Hoppe RT. Clinical stage IA (limited patch and plaque) mycosis fungoides: a long-term outcome analysis. Arch Dermatol. 1996;132(11):1309-1313. (Pubitemid 26386618)
17. Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139(7):857-866. (Pubitemid 36898920)
18. Whittaker SJ, Marsden JR, Spittle M, Russell Jones R; British Association of Dermatologists; U. K. Cutaneous Lymphoma Group. Joint British Association of Dermatologists and U. K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol. 2003;149(6):1095-1107. (Pubitemid 38058085)
19. National Comprehensive Cancer Network NCCN guidelines: Clinical Practice Guidelines in Oncology Version 4.2011: non-Hodgkin's lymphomas: mycosis fungoides/Sézary syndrome. http://www.nccn.org. Accessed August 28, 2011.
20. Duvic M, Olsen EA, Omura GA, et al. A phase III, randomized, double-blind, placebocontrolled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2001;44(6):940-947. (Pubitemid 32493443)
21. Pimpinelli N, Olsen EA, Santucci M, et al; International Society for Cutaneous Lymphoma. Defining early mycosis fungoides. J Am Acad Dermatol. 2005;53(6):1053-1063.
22. Heald P, Mehlmauer M, Martin AG, Crowley CA, Yocum RC, Reich SD; Worldwide Bexarotene Study Group. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol. 2003;49(5):801-815. (Pubitemid 37314867)
23. Olsen EA, Whittaker S, Kim YH, et al; International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Consortium for Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29(18):2598-2607.
24. Stevens SR, Ke MS, Parry EJ, Mark J, Cooper KD. Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the Severity-Weighted Assessment Tool (SWAT). Arch Dermatol. 2002;138(1):42-48. (Pubitemid 34056233)